Showing 4251-4260 of 6036 results for "".
- Bausch + Lomb and Glaucoma Research Foundation Launch 'Faces of Glaucoma' Campaignhttps://modernod.com/news/bausch-lomb-and-glaucoma-research-foundation-launch-faces-of-glaucoma-campaign/2482039/Bausch + Lomb and the Glaucoma Research Foundation (GRF) have launched “Faces of Glaucoma,” a campaign that will highlight diverse patient stories and raise awareness of the second leading cause of blindness worldwide. The campaign will run through January, which is Glaucoma
- Aetna Rolls Back Prior Authorization for Cataract Surgeries for Medicare Advantage Beneficiaries in Georgiahttps://modernod.com/news/aetna-rolls-back-prior-authorization-for-cataract-surgeries-for-medicare-advantage-beneficiaries-in-georgia-1/2482030/After 2 years of advocacy from the ophthalmology community, Aetna confirmed in a letter to the American Academy of Ophthalmology that it will no longer require preapproval for cataract surgeries for Medicare Advantage beneficiaries in Georgia, starting Jan.1. Last year, the insurer rolled back th
- Visiox Pharmaceuticals to be Listed on Nasdaq Through Combination with PowerUp Acquisitionhttps://modernod.com/news/visiox-pharmaceuticals-to-be-listed-on-nasdaq-through-combination-with-powerup-acquisition/2482029/Visiox Pharmaceuticals and PowerUp Acquisition Corp. announced the execution of a definitive agreement for a business combination that would result in Visiox becoming a publicly traded company on the Nasdaq Capital Market. The business combination is expected to close in the first quarter of
- iSTAR Medical Continues European Expansion with First MINIject Surgeries in the Netherlandshttps://modernod.com/news/istar-medical-continues-european-expansion-with-first-miniject-surgeries-in-the-netherlands/2482027/iSTAR Medical announced the successful first implantations of MINIject, the company’s bio-integrating, minimally-invasive glaucoma surgery (MIGS) device, in the Netherlands. Patients were successfully implanted at the University Eye Clinic of the Maastricht University Medical Center+ b
- ECM Therapeutics Collaborates with the University of Pittsburgh Vision Institute to Advance Technology for Optic Nerve Repairhttps://modernod.com/news/ecm-therapeutics-collaborates-with-the-university-of-pittsburgh-vision-institute-to-advance-technology-for-optic-nerve-repair/2482023/ECM Therapeutics announced a collaboration with the Louis J. Fox Center for Vision Restoration at the UPMC and Pitt Vision Institute to leverage a platform technology called Matrix Bound Nanovesicles (MBV) that has recently shown potential to promote restoration of injure
- Nordic Pharma Completes Acquisition of Visant Medical; Plans to Launch Lacrifill in the US for Dry Eye Diseasehttps://modernod.com/news/nordic-pharma-completes-acquisition-of-visant-medical-plans-to-launch-lacrifill-in-the-us-for-dry-eye-disease/2482021/Amring Pharmaceuticals, a subsidiary of Nordic Group BV (Nordic Pharma), announced the completion of its acquisition of Visant Medical. Financial terms of the deal were not disclosed. The companies say the acquisition unites Nordic Pharma's pharmaceutical e
- Carl Zeiss Meditec to Acquire Dutch Ophthalmic Research Center (DORC)https://modernod.com/news/carl-zeiss-meditec-to-acquire-dutch-ophthalmic-research-center-dorc/2482014/In a move to expand its position in the vitreo-retinal surgery segment and strengthen its position in the ophthalmic medical device category globally, Carl Zeiss Meditec announced it has entered into an agreement to acquire 100% of the shares in Dutch Ophthalmic Research Cente
- Clearside Biomedical Completes Randomization in Phase 2b Clinical Trial of CLS-AX in Wet AMDhttps://modernod.com/news/clearside-biomedical-completes-randomization-in-phase-2b-clinical-trial-of-cls-ax-in-wet-amd/2482013/Clearside Biomedical announced it has completed randomization in its ODYSSEY Phase 2b clinical trial of CLS-AX (axitinib injectable suspension) in wet age-related macular degeneration (AMD). Topline data results are expected in the third quarter of 2024. “As we continue
- Ashley Magargee Named CEO of Genentechhttps://modernod.com/news/genentech-names-ashley-magargee-as-ceo/2482008/Ashley Magargee has been appointed Chief Executive Officer (CEO) of Genentech, effective January 1, 2024. In addition to her role as Head of US Commercial Portfolio, Ms. Magargee has been serving as ad interim CEO since the departure of Alexander Hardy on November 1, 2023. She will repo
- Ocugen Announces First Patient Dosed in Phase 1/2 Trial of OCU410 Modifier Gene Therapy for GAhttps://modernod.com/news/ocugen-announces-first-patient-dosed-in-phase-12-trial-of-ocu410-modifier-gene-therapy-for-ga/2482006/Ocugen announced that the first patient has been dosed in the ArMaDa phase 1/2 clinical trial of OCU410 (AAV-RORA), a modifier gene therapy product candidate being developed for dry AMD (AMD). This phase 1/2 trial will assess the safety and efficacy of OCU410 for geographic at